Baclofen for Spasticity Management
Baclofen should be reserved for spasticity causing pain, poor skin hygiene, or decreased function, using a stepwise approach starting with oral formulation (starting 5 mg TID, titrating gradually) and escalating to intrathecal delivery only when oral therapy fails at maximum tolerated doses. 1
Treatment Algorithm
Step 1: Non-Pharmacologic Management (First-Line)
Before initiating baclofen, implement:
- Positioning and passive stretching several times daily
- Range of motion exercises
- Splinting or serial casting for contractures
- Surgical correction if needed
These interventions should be attempted first, as no reliable data exist comparing physical therapy interventions with or without antispastic medications 1
Step 2: Oral Baclofen (Second-Line)
Indications for oral baclofen 2:
- Spasticity from multiple sclerosis (particularly flexor spasms, pain, clonus, muscular rigidity)
- Spinal cord injuries and other spinal cord diseases
- NOT indicated for stroke, cerebral palsy, or Parkinson's disease (efficacy not established)
Dosing approach:
- Start low due to sedation risk
- Titrate gradually based on response
- Monitor for excessive weakness, which is dose-related
- Note: Oral baclofen causes significant sedation and has less impact on spasticity in stroke victims compared to other conditions 1
Critical caveat: Oral baclofen reportedly has less impact on spasticity in stroke patients compared to spinal cord conditions, making it a less favorable choice in that population 1
Step 3: Intrathecal Baclofen (Third-Line)
Indications 1:
- Chronic patients (>6 months from injury/onset) with spasticity causing pain, poor skin hygiene, or decreased function
- Failed maximum doses of oral baclofen, tizanidine, and/or dantrolene
- >80% of patients show improvement in tone; >65% improve in spasms 3
Dosing patterns from long-term data 4, 5:
- Multiple sclerosis: Stabilizes at mean 323 μg/day after 2 years (range 22-1400 μg/day, most patients 90-703 μg/day)
- Spinal cord injury: Stabilizes at mean 504 μg/day after 5 years (significantly higher than MS)
- No long-term tolerance develops - doses stabilize and do not progressively increase 4
- Average 1-year dose: 191.93 μg/day for MS patients 5
Trial dosing protocol 6:
- Bolus test via lumbar puncture: 50,75, or 100 μg
- Assess response for minimum 4 hours
- Expect Ashworth score reduction from mean 3.8 to 1.5
- Expect spasm score reduction from mean 3.5 to 1.2
- Only implant pump in responders
Monitoring Requirements
Safety Monitoring 2:
- Seizure control and EEG in epileptic patients (deterioration reported occasionally)
- Ovarian cysts in females (4% incidence vs 1-5% spontaneous rate; usually resolve spontaneously)
- Renal function - limited data suggest high risk in renal disease patients
- Avoid alcohol and CNS depressants - additive effects
Functional Monitoring:
- Caution when spasticity maintains upright posture or balance - reducing spasticity may worsen function 2
- In ambulatory patients: 87% maintained walking ability at 1 year, 62% long-term (mean 3.4 years) 7
Complications
Intrathecal baclofen complication rate: 1% per month (0.011 per month) 4
- 74% are catheter-related problems (most common complication)
- Pump malfunctions less common
- Withdrawal syndrome is the most serious risk - can cause seizures, psychic symptoms, hyperthermia, potentially death if untreated 3
- Overdose primarily from test doses or programming errors
Oral baclofen adverse effects (10-75% incidence) 3:
- Sedation/somnolence
- Excessive weakness (dose-related)
- Vertigo
- Psychological disturbances
- Most are transient and reversible
Critical Pitfalls to Avoid
Never abruptly discontinue baclofen - withdrawal can cause seizures and severe symptoms requiring immediate reinstitution 3
Do not use in acute stroke recovery period - may have deleterious effects on recovery 1
Screen for response before pump implantation - all patients must undergo bolus test dosing 8, 6
Tolerance development: 3 of 19 patients (16%) in one study required >1000 μg/day with poor response, suggesting some patients develop tolerance despite overall data showing stable long-term dosing 6
Pediatric use: Safety and effectiveness not established in children <12 years 2
Comparative Context
Tizanidine may be preferred over baclofen for chronic stroke patients specifically, showing efficacy with improvement in spasticity and pain without loss of motor strength 1. However, for spinal cord injury and multiple sclerosis, baclofen remains the most commonly prescribed antispasmodic 9.